Hansoh Pharma's Lung Cancer Drug Aumseqa Has EU Marketing Authorization Revoked Due to Procedural Issue

The European Commission has revoked the EU marketing authorization for Hansoh Pharma's lung cancer drug aumolertinib (Aumseqa). The company stated that the revocation, which occurred on September 25, 2026, stems from a procedural issue related to data protection for a background reference cited in its application, rather than concerns about the drug's quality, safety, or efficacy. Hansoh Pharma plans to resubmit its application to the EMA promptly.

Context

Aumseqa, developed by Hansoh Pharma, received initial marketing authorization from the European Commission for its use in lung cancer treatment. The recent revocation is not due to any safety or efficacy concerns, but rather a procedural issue regarding data protection. This situation illustrates the complexities involved in drug approval processes within the European Union.

Why it matters

The revocation of Aumseqa's marketing authorization highlights the importance of regulatory compliance in the pharmaceutical industry. This incident may affect patient access to the drug, which is used for treating lung cancer. It also underscores the need for companies to ensure that all procedural requirements are met to avoid disruptions in the approval process.

Implications

The revocation may temporarily limit patient access to Aumseqa in the EU market, impacting those who rely on the drug for treatment. Healthcare providers may need to consider alternative therapies for their patients during this period. The incident could also influence how other pharmaceutical companies approach regulatory compliance and data protection in their applications.

What to watch

Hansoh Pharma intends to resubmit its application to the European Medicines Agency (EMA) in the near future. Observers will be looking for updates on the timeline for this resubmission and any changes made to address the procedural issue. Additionally, the response from the EMA regarding the new application will be critical.